Evidence-based review of safety and efficacy in cerebral palsy

被引：13
作者：
Tilton, Ann Henderson [1 ]
机构：
[1] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA
来源：
TOXICON | 2015年 / 107卷
关键词：
Cerebral palsy; Botulinum toxin; BOTULINUM-TOXIN-A; ADVERSE EVENTS; CHILDREN; INJECTIONS; CLASSIFICATION; ADOLESCENTS; DEFINITION; SPASTICITY; THERAPY; LIMBS;
D O I：
10.1016/j.toxicon.2015.09.020
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The introduction of botulinum toxin has been a major advance in the care of children with cerebral palsy. Clinically the positive effects of treatment with botulinum toxin are seen in patients with all levels of GMFCS. Botulinum toxin has been established in multiple studies to reduce spasticity in the upper and lower extremities, although there is some conflicting evidence regarding function. The medication is felt to be generally safe with a low incidence of adverse events which are temporary and self-limited. However there is the recognition that severe weakness may rarely occur. Ultimately it is incumbent upon the physician to consider both risks and benefits in determining the best treatment plan for the individual patient. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：105 / 108
页数：4
相关论文
共 25 条
  • [1] Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials
    Albavera-Hernandez, Cidronio
    Rodriguez, Jorge M.
    Idrovo, Alvaro J.
    [J]. CLINICAL REHABILITATION, 2009, 23 (05) : 394 - 407
  • [2] [Anonymous], 2008, BOTULINUMTOXIN UNERW
  • [3] Proposed definition and classification of cerebral palsy, April 2005 - Introduction
    Bax, M
    Goldstein, M
    Rosenbaum, P
    Leviton, A
    Paneth, N
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2005, 47 (08) : 571 - 576
  • [4] Use of Rimabotulinum Toxin for Focal Hypertonicity Management in Children with Cerebral Palsy with Nonresponse to Onabotulinum Toxin
    Brandenburg, Joline E.
    Krach, Linda E.
    Gormley, Mark E., Jr.
    [J]. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2013, 92 (10) : 898 - 904
  • [5] Onabotulinumtoxin A® injections: A safety review of children with clubfoot under 2 years of age at BC Children's Hospital
    Chhina, Harpreet
    Howren, Alyssa
    Simmonds, Andrea
    Alvarez, Christine M.
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2014, 18 (02) : 171 - 175
  • [6] COSGROVE AP, 1994, DEV MED CHILD NEUROL, V36, P379
  • [7] Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
    Delgado, M. R.
    Hirtz, D.
    Aisen, M.
    Ashwal, S.
    Fehlings, D. L.
    McLaughlin, J.
    Morrison, L. A.
    Shrader, M. W.
    Tilton, A.
    Vargus-Adams, J.
    [J]. NEUROLOGY, 2010, 74 (04) : 336 - 343
  • [8] Botulinum toxin type A treatment in children with cerebral palsy: Evaluation of treatment success or failure by means of goal attainment scaling
    Desloovere, Kaat
    Schorkhuber, Verena
    Fagard, Katrien
    Van Campenhout, Anja
    De Cat, Jos
    Pauwels, Petra
    Ortibus, Els
    De Cock, Paul
    Molenaers, Guy
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2012, 16 (03) : 229 - 236
  • [9] The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response
    Eames, NWA
    Baker, R
    Hill, N
    Graham, K
    Taylor, T
    Cosgrove, A
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 1999, 41 (04) : 226 - 232
  • [10] Safety of botulinum toxin type A in children younger than 2 years
    Ignacio Pascual-Pascual, Samuel
    Pascual-Castroviejo, Ignacio
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2009, 13 (06) : 511 - 515
123